Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Issued (2019 - 2025)

X4 Pharmaceuticals' Shares Issued history spans 7 years, with the latest figure at $146.0 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 108077.78% year-over-year to $146.0 million; the TTM value through Dec 2025 reached $238.8 million, up 60657.76%, while the annual FY2025 figure was $238.5 million, 81032.65% up from the prior year.
  • Shares Issued reached $146.0 million in Q4 2025 per XFOR's latest filing, up from $92.4 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $146.0 million in Q4 2025 to a low of $2000.0 in Q3 2023.
  • Average Shares Issued over 5 years is $21.8 million, with a median of $116000.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: crashed 57.29% in 2021, then skyrocketed 108077.78% in 2025.
  • A 5-year view of Shares Issued shows it stood at $103000.0 in 2021, then soared by 33.98% to $138000.0 in 2022, then dropped by 29.71% to $97000.0 in 2023, then skyrocketed by 39.18% to $135000.0 in 2024, then surged by 108077.78% to $146.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Shares Issued are $146.0 million (Q4 2025), $92.4 million (Q3 2025), and $135000.0 (Q4 2024).